STOCKHOLM, June 30,
2022 /PRNewswire/ -- During June, Calliditas
Therapeutics AB (publ) has issued 5,908,018 class C-shares as part
of the establishment of the company's at-the-market program. Thus,
as of June 30, 2022, the number of
shares and votes in the company amounts to 59,106,188 shares and
53,788,971.8 votes.
For further information, please contact:
Mikael Widell
Investor relations
Tel.: +46703119960
email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas
Therapeutics AB (publ) is required to disclose pursuant to the
Swedish Financial Instruments Trading Act. The information was
submitted for publication, through the agency of the contact
persons set out above, at 10:00 a.m.
CEST on June 30, 2022.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, TARPEYOTM (budesonide) delayed release
capsules, has been approved by the FDA. This drug product is
awaiting European Commission (EC) approval following a positive
CHMP opinion. Additionally, Calliditas is conducting a Phase
2b/3 trial with its NOX inhibitor
product candidate setanaxib in primary biliary cholangitis and is
initiating a head and neck cancer Phase 2 trial with setanaxib.
Calliditas' common shares are listed on Nasdaq Stockholm (ticker:
CALTX) and its American Depositary Shares are listed on the Nasdaq
Global Select Market (ticker: CALT).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c3593813
The following files are available for download:
|
https://mb.cision.com/Main/16574/3593813/1598913.pdf
|
Number of shares and
votes June 2022 (Eng)
|
View original
content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301578626.html
SOURCE Calliditas Therapeutics